Novel Intraocular Melanoma Treatment options are getting better with the advent of laser surgery that removes the affected cells

 

Intraocular Melanoma Treatment

Intraocular Melanoma is the most common form of skin cancer that affects the iris of the eye. It is also one of the most difficult to treat and may leave scars or no visible scar if proper medical treatment is given. Treatment options are often limited due to its advanced stage, however, it is still possible for this disease to be removed surgically. It is important to seek medical treatment if any of these symptoms are present. Melanoma is a type of skin cancer that generally occurs on the iris of the eye, which is the colored part of the eyeball. This can cause permanent damage to the iris and result in impaired vision.

This is the most common cause of vision loss in humans. There are other less common causes of this condition, however, it is not always possible to determine this in every case. Intraocular melanoma is a difficult condition to treat. It is often resistant to the most common forms of intraocular melanoma treatment available. Doctors often resort to removing the mole or getting it surgically removed in an attempt to cure the condition. However, removal of the mole usually results in a scar being left behind. If the medical treatment does not completely cure the condition, other forms of treatment including laser surgery to remove the affected cells of the melanoma continue to be performed.

Intraocular melanoma is the most common cause of vision loss in humans. However, there are other less common causes of vision loss. Some forms of skin cancer can cause temporary or permanent vision loss. These include squamous cell lung cancer and melanoma. Furthermore, some forms of cancer are linked to the development of vision loss. For instance, if the melanoma that causes the vision problem is associated with a primary tumor then the intraocular melanoma treatment for the primary tumor is often used in conjunction with medical treatment to treat the melanoma. Recently, in February 2019, Provecturs received the orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for small molecule oncolytic immunotherapy PV-10 for the treatment of ocular melanoma. 


Comments

Popular posts from this blog

Light Linear Alpha Olefins Are Produces through Oligomerization of Ethylene and by Fischer-Tropsch Synthesis

Cervical Cancer Diagnostic Tests have become highly sophisticated with accurate diagnosis for effective treatment

Beta Glucan-based products have been shown to be effective in lowering cholesterol and preventing heart disease